Objective Cancer care has been disrupted by the response of health systems to the COVID-19 pandemic, especially during lockdowns. The objective of our study is to evaluate the impact of the pandemic on the incidence of cancer diagnoses in primary care.
Design Time-series study of malignant neoplasms and diagnostic procedures, using data from the primary care electronic health records from January 2014 to September 2020.
Setting Primary care, Catalonia, Spain.
Participants People older than 14 years and assigned in one of the primary care practices of the Catalan Institute of Health with a new diagnosis of malignant neoplasm.
Main outcome measures We obtained the monthly expected incidence of malignant neoplasms using a temporary regression, where the response variable was the incidence of cancer from 2014 to 2018 and the adjustment variables were the trend and seasonality of the time series. Excess or lack of malignant neoplasms was defined as the number of observed minus expected cases, globally and stratified by sex, age, type of cancer and socioeconomic status.
Results Between March and September 2020 we observed 8766 (95% CI 4135 to 13 397) fewer malignant neoplasm diagnoses, representing a reduction of 34% (95% CI 19.5% to 44.1%) compared with the expected. This underdiagnosis was greater in individuals aged older than 64 years, men and in some types of cancers (skin, colorectal, prostate). Although the reduction was predominantly focused during the lockdown, expected figures have not yet been reached (40.5% reduction during the lockdown and 24.3% reduction after that).
Conclusions Reduction in cancer incidence has been observed during and after the lockdown. Urgent policy interventions are necessary to mitigate the indirect effects of the COVID-19 pandemic and related control measures on other diseases and some strategies must be designed in order to reduce the underdiagnosis of cancer.
- primary care
Data availability statement
Data are available in a public, open access repository. All data and analytical code are provided at https://github.com/ErmengolComa/neos.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Strengths and limitations of this study
We used good-quality data from primary care electronic health records covering about five million people and 75% of the Catalan population.
Our estimation used data from 5 years and we validated our method in a year not affected by the COVID-19 pandemic.
Our analysis extends the first wave of COVID-19-related effects and lasted for 7 months.
We used ecological data and we were not allowed to ensure a causal correlation between reductions in the incidence of cancer and the COVID-19 pandemic.
COVID-19, caused by the SARS-CoV-2 virus, started as an outbreak in Wuhan (China)1 and quickly evolved into a global pandemic.2 The first cases in Europe were identified in France on 24 January 20203 and the first official case in Catalonia (Spain) was reported a month later on 25 February. In a few months, COVID-19 has become one of the greatest public health challenges in recent times. By 5 November 2020, SARS-CoV-2 has infected over 48 million people worldwide and caused more than 1 233 000 deaths.4 In Catalonia, as of the same date, official figures stated there have been 290 244 confirmed COVID-19 cases and 14 482 deaths.5
In the absence of a vaccine, a social distancing strategy has been the primary intervention to reduce the spread of the epidemic and COVID-19-related deaths.6 In many countries, this strategy includes a national lockdown.6 In Spain, lockdown was adopted on 14 March.7 During and after the lockdown, governments advocated that patients communicated with their general practitioners by phone, encouraged people to stay at home and work from home, cancelled non-essential healthcare services, restricted some diagnostic and therapeutic procedures to urgent cases only, and scaled down most routine preventive activities.8 Despite the need for these measures to control the epidemic and reduce COVID-19 mortality,9 many studies point out collateral health damages. In fact, a reduction in preventive care measures, such as screening10 or childhood vaccination,11 diagnosis,12 and control of chronic diseases in primary care,13 was reported. In addition, some studies highlighted an increase in mental illness14 as well as all-cause mortality.15
Cancer care has also been disrupted by the response of health systems to the pandemic.16 Some studies have highlighted the problem of access to and utilisation of cancer services during and after the first wave of SARS-CoV-2.17–19 Some examples are limitations of access to screening programmes, to medical care cancer-related visits (both in primary care and in hospitals), to cancer diagnostic tests, reduction in scheduled cancer surgeries due to limited access to postsurgical critical care units and occupation of hospital beds by patients with COVID-19, reduction of treatments that could pose a high risk to the patient in the circumstances of the pandemic, and modifications of therapeutic guidelines, among others.18–21 In some countries, a reduction in cancer diagnostics and cancer encounters was observed.22–24 This led to a reduction in new cancer diagnoses and a delay in cancer treatment.25 26 There is evidence that progression of cancers during these delays (even short delays of 3 months for more aggressive cancers) will impact on patients’ long-term survival.24 27 In the UK, substantial increases in the number of avoidable cancer deaths are to be expected as a result of delays in diagnosis due to the COVID-19 pandemic.28 As some projections have estimated that COVID-19-related disruption in healthcare may last for more than 18 months,24 it is crucial to promptly quantify the effects on cancer diagnosis in any health system in order to mitigate their negative effects.
Considering that the future of the COVID-19 pandemic is currently unknown, we need to ensure that patients continue to receive proper cancer care in order to minimise the clinical impact of a diagnostic delay due to COVID-19-related dysfunctions. The aim of this study is to analyse and interpret the impact of the COVID-19 pandemic on the incidence of malignant neoplasms through the analysis of primary care electronic health records (EHR) data in Catalonia.
Design and data source
We performed a time-series study of malignant neoplasms case reported diagnoses. Data were extracted from primary care EHR of the Institut Català de la Salut (Catalan Institute of Health; or ICS, its Catalan initials). ICS is the main primary care provider in Catalonia. It manages around 75% of all primary care practices (PCPs) in the Catalan public health system and covers about 5.8 million people. Its population is highly representative of the population of Catalonia in terms of geographical area, age distribution and gender.29 In 2005, ICS implemented a universal EHR system for use in primary care, known as ECAP (Estació Clínica d’Atenció Primària), which is a software system that serves as a repository for structured data on diagnoses (coded according to the International Classification of Diseases 10th revision, ICD-10), clinical variables, prescription data, laboratory test results and diagnostic requests. Data from ICS’ primary care EHR, including cancer diagnoses, have been previously validated in several studies.30
Participants and study period
We included all patients older than 14 years old with a malignant neoplasm diagnosis registered in the EHR (see ICD-10 codes in online supplemental material 1). The study period included all months between January 2014 and September 2020. We divided this period into three for the time-series analysis: training (2014–2018), validation (2019) and analysis (2020). In addition, we separated the year 2020 available months into two periods for calculation of reductions in cancer incidence: ‘lockdown period’ from March to June, coinciding with the state of alarm in Spain (including the lockdown and different phases of de-escalation), and ‘postlockdown period’ from July to September, after the state of alarm.
The main variable was diagnosis of malignant neoplasms. Monthly incidence rates of malignant neoplasm per 105 population were calculated.
Time-series analyses were performed globally, by sex, age groups (15–64 years old and >64 years old), type of neoplasm, socioeconomic status and rurality. We assessed the socioeconomic status using the validated deprivation index based on census data (MEDEA deprivation index) constructed by the project Mortality and socio-economic and environmental inequalities in small areas of cities in Spain (MEDEA project).31 We categorised the MEDEA Deprivation Index into quartiles, where first and fourth quartiles are the least and the most deprived areas, respectively. Rural areas were categorised separately and were defined as areas with less than 10 000 inhabitants and a population density lower than 150 inhabitants/km2.
We also performed the same time-series analysis for some related cancer diagnostic procedures with data available, such as mammograms, colonoscopies and chest radiographies.
We calculated monthly malignant neoplasm and diagnostic procedures incidence rates per 105 population as the number of new diagnoses or procedures divided by the number of alive population assigned to ICS PCPs and multiplied by 100 000 (source of the population: ECAP).
We obtained the expected incidence for the study period using a time-series regression, where the response variable was the incidence rate per 105 inhabitants from 2014 to 2018, and the adjustment variables were the trend and seasonality of the time series. Data set was divided into three sets: training set (from 2014 to 2018), validation set (2019) and analysis set (2020). We used the training set to adjust the model and validation set to test our method as a sensitivity analysis. We checked whether our method identified any excess or reduction in the monthly incidence rates in a regular year not affected by the COVID-19 pandemic. Finally, we projected the estimated time series to our analysis set.
The number of expected cancer diagnoses for each period was obtained multiplying the projected incidence by the population and dividing by 100 000. Excess or lack of malignant neoplasms and diagnostic procedures were defined as the number of observed minus expected diagnoses, estimated monthly and only for the periods where observed incidence was under the lower 95% CIs of the time series. We also calculated the percentage of reduction as follows: (number of observed diagnoses−number of expected diagnoses)/number of expected diagnoses. This percentage was also calculated for the lockdown period and the postlockdown period. We calculated 95% CI for each estimate.
Patient and public involvement statement
This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.
The population structure assigned to Catalan PCP and used to calculate cancer incidence rates has remained stable in the study period in terms of age and gender, as shown in table 1.
From January 2014 to September 2020, 273 379 new malignant neoplasms were registered in primary care. This represents a monthly average incidence per 105 population of 72.4 during the 2014–2018 period, 72.8 during 2019 and only 54.6 during 2020. From January to September 2020, 24 265 new cancers were recorded, of which 47.3% were women and 63.5% older than 64 years, with similar distribution to previous years. Regarding the type of cancer, non-melanoma skin cancers accounted for 24.8% of all new cancers diagnosed in 2020. Online supplemental material 3 provides the number and monthly incidence average for each type of cancer and other variables for the three periods considered in our study.
Figure 1 shows the observed and estimated rates of monthly new malignant neoplasm diagnoses (with 95% CI) since January 2019. Observed incidences were as expected for 2019 and the first 2 months of 2020. Since March 2020, observed incidences of malignant neoplasms were significantly lesser than expected, for the whole population and by age groups.
We estimated that the difference between the expected and observed diagnoses accounted for 8766 fewer cancers (95% CI 4135 to 13 397) from March to September. This represents a reduction of 34% in the diagnosis of malignant neoplasm compared with the expected. This reduction was greater during the lockdown period, with 40.5% (95% CI 28.2% to 49.2%) reduction compared with expected, vs 24.3% (95% CI 6.2% to 36.5%) for the postlockdown period (table 2). The months with greater reduction were April, May and March, with reductions of 59.3% (95% CI 50% to 65.7%), 45.5% (95% CI 34.8% to 53.2%) and 36% (95% CI 23.2% to 45.1%), respectively. Detailed expected cases and the number and percentages of cancer reductions by month are shown in online supplemental material 4, stratified by age group, sex, socioeconomic status and type of cancer.
The estimated number of underdiagnosed malignant neoplasms and the percentage of underdiagnoses compared with the expected are presented stratified by age, sex, type of neoplasm, socioeconomic status and rurality in table 2. Population older than 64 years had greater reduction than the population between 15 and 64 years: 35.2% (95% CI 19.6% to 45.7%) vs 25.2% (95% CI 15.4% to 32.1%). Regarding sex, reduction in men was greater than in women: 36.1% (95% CI 20.8% to 46.4%) and 31.6% (95% CI 16.8% to 41.8%), respectively (figure 2 and table 2).
Regarding the type of cancer, we found that in all cancers observed incidences were lesser than expected since March 2020 (figure 3 and table 2). This reduction was greater in April and since then the incidence started to increase, although still under the 95% CI until August, with big differences between the types of cancer. Non-melanoma skin cancers were those with higher reductions with 3118 fewer cancers (95% CI 1807 to 4429), followed by colorectal cancer with 568 fewer cancers (95% CI 167 to 970), representing a reduction of 27.3% (95% CI 11% to 36.7%), and prostatic cancers with 539 fewer cancers (95% CI 189 to 890) and 33.3% reduction (95% CI 16.7% to 42.2%), compared with the expected. Breast and lung new cancers were moderately reduced compared with other types of cancers: 17.1% (95% CI 10.9% to 21.3%%) and 20% (95% CI 4% to 28.5%), respectively. Incidences in lung cancer were under the 95% CI for fewer months than the other types of cancer, as shown in figure 3. In addition, all reductions in breast cancer were during the lockdown period.
The same pattern and reduction of new malignant diagnosis were observed in all socioeconomic status (figure 4 and table 2), although in rural areas it was the least, with 21.3% (95% CI 13.4% to 26.7%) reduction and only 3 months of statistical differences between observed and expected. Urban least and most deprived areas accounted for similar reduction, although with some differences between periods. The least deprived areas had greater reduction during the lockdown period (45.5% vs 39.9% in the most deprived). Nonetheless, the least deprived areas accounted for less reduction after the lockdown.
Finally, figure 5 shows the observed and estimated rates per 105 population of monthly new mammograms, colonoscopies and chest radiographies. We observed a reduction in mammograms and colonoscopies during the same months as we observed for neoplasms and an excess of chest radiographies during April 2020. The reduction in procedures accounted for 16 219 fewer colonoscopies (95% CI 10 836 to 21 603) and for 15 099 fewer mammograms (95% CI 10 974 to 19 223) (table 2). In addition, reduction in mammograms was only observed during the lockdown period.
Our study analyses the effects of the COVID-19 pandemic and related control measures on cancer diagnosis. We found a reduction of more than 8700 new cancers since March 2020, representing 34% fewer cancers than expected. This reduction was greater during the months of March, April and May, temporarily overlapping with the lockdown measures established in Spain in mid-March 2020.7 However, the reduction in new diagnoses of cancer extended beyond the end of the lockdown, especially for people older than 64 years, men, most deprived areas and some types of cancer. Our work also shows similar reductions in some cancer diagnostic procedures during the same period. Although this negative effect on the incidence of cancers appeared to occur across all ages, sex and socioeconomic status, the most deprived areas had greater reduction after the lockdown (29.4% vs 19.8%) and recovered worse than the least deprived. These deprived areas should be areas of special attention and priority areas of governments’ actions and control measures to reduce pre-existing inequalities that COVID-19 has exacerbated and highlighted.33–35
Other studies found similar results in many countries.12 22 25 33 36 For example, reductions in cancer diagnoses in Italy37 accounted for 39% and for 29% in Slovenia.25 In addition, a reduction of 48%, 75% and 42% was observed for X-rays, mammograms and ultrasounds in Slovenia,25 and colonoscopy has been reduced by 80% in Argentina.36 Some of these reductions are related to a suspension or decline in cancer screening services.22 26 38 39 However, some studies pointed out that the reductions in diagnostic procedures are also related to a decrease in cancer encounters, leading to a reduction in diagnostic suspicion22 and therefore a treatment delay.40
Our study reveals that almost all cancers have been affected. Nonetheless, the reduction in new cancer diagnoses ranged between 43.7% in non-melanoma skin cancers and 17.1% in breast cancers. These differences between cancers are consistent with the impact on cancer diagnosis described in several studies, although these works are mainly focused on the first wave of the COVID-19 period. In Italy, colorectal cancer has decreased by 62% and prostate cancer by 75%, having the greatest reductions, while breast cancer was moderately reduced (26%).37 In the UK, patients with new melanoma dropped by 67.1%, while lung cancer was the least altered (46.8% reduction).22 Dutch researchers also found differences in cancer reductions between non-skin cancers (26%) and skin cancers (60%).26
Several reasons may explain our results. First, during the lockdown, all non-essential health activities were interrupted and authorities advised the population to stay at home. In addition, Spain was heavily hit by COVID-19 in March to May, the health system collapsed, and many diagnostic procedures were halted, except those used to diagnose some complications of COVID-19, such as chest radiography or thoracic CT scans. However, even after the lockdown restrictions, cancer incidence did not achieve the expected results, suggesting that measures to control the pandemic still have side effects on the diagnosis of cancer as well as other diseases. Second, face-to-face visits have dropped drastically since March and have been replaced by telehealth,41 making it more difficult to appraise signs and symptoms and to initiate an investigation for a cancer diagnosis, especially for some populations such as the more socioeconomic disadvantaged individuals who are less likely to engage in telemedicine.42 43 Lastly, studies also suggested some reasons linked to health-seeking behaviour of patients or the fear of being infected by SARS-CoV-2.19 26 44 45
The 34% decrease in the incidence of new cancers in our study is considered to be concerning, although the effects of these reductions are still uncertain as the impact of the pandemic on patients with cancer can only be reliably assessed after a reasonable time. Some studies estimated an increase in the total years of life lost, excess mortality and other consequences,17 24 38 46–50 although these may differ according to tumour type,18 50–52 as some cancers such as lung, pancreatic or breast progress rapidly and require immediate diagnosis and treatment to prevent adverse outcomes.
Our study has some limitations. First, we performed a time-series study with ecological data. This approach does not allow to ensure a causal correlation between reduction in the incidence of malignant neoplasm and the COVID-19 pandemic, although the reduction in the observed data around the start of the state of alarm in March 2020 is clear. Second, as our analysis is based on crude rates, major changes in population structure could limit the use of the proposed method, but since population age and gender distribution has remained relatively stable in the study period we have maintained crude rate analysis for a straightforward reporting of the volume of cancer reductions. Finally, given that COVID-19 hit Spain hard with an excess of 44 000 deaths,53 some can argue that part of the reduction of the incidence of malignant neoplasms could be linked to the harvesting effect, where some patients who could have been diagnosed had deceased. Even so, we observed a reduction in cancers in all age groups, while the excess of deaths caused by COVID-19 was mostly in the elderly.53
Despite the limitations, this study also has strengths. Several studies have used the Catalan primary care EHR data to perform useful research in real-world conditions.31 54 Moreover, our estimation used data from 5 years and we validated our method with 2019 diagnoses, where we did not find any excess or reduction in the incidence of cancer, strengthening our findings in 2020. In addition, our analysis extends the first wave of COVID-19-related effects and lasted for 7 months in contrast to other studies focused on lockdown period only. We also assessed the socioeconomic differences, identifying the most affected areas that should be a priority during the following months. As ICS manages about three in every four practices in Catalonia, our results are generalisable and our method could be introduced to other settings that also use EHR. That way, our findings could be confirmed in other countries.
In conclusion, our study shows a reduction in registered cancer incidence during the COVID-19 pandemic, suggesting delays in cancer diagnosis, which may lead to negative health outcomes. We must continue to control the pandemic, but we also need to ensure that common causes of morbidity and mortality are also taken into account when decisions are made. Urgent policy interventions are necessary to mitigate possible effects on other diseases. In addition, long-term studies should be performed in order to evaluate the future effects of this situation.
Data availability statement
Data are available in a public, open access repository. All data and analytical code are provided at https://github.com/ErmengolComa/neos.
This study was done in accordance with existing statutory and ethical approvals from the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/172-PCV).
We would like to acknowledge the efforts of all members of the SISAP team during the last months. We would also like to thank all the primary care healthcare professionals in Catalonia during these challenging times. We also thank Ada Ferrer for her valuable contribution to language editing of the manuscript.
Twitter @ErmengolComa, @mmarzoc
Contributors EC, CG, NM, MM-C, MB, LM-B, MF, FF, AM and MM contributed to the design of the study, interpretation of the results and reviewed the manuscript. EC, FF and NM had access to the data, performed the statistical analysis and acted as guarantors. EC, CG, MM-C, MB and NM wrote the first draft of the manuscript. All authors critically revised the manuscript. The corresponding author attests that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.